{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:45:18Z","timestamp":1789854318174,"version":"4.0.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T00:00:00Z","timestamp":1516752000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"DOI":"10.3389\/fpsyt.2018.00002","type":"journal-article","created":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T23:15:59Z","timestamp":1516749359000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":38,"title":["Pharmacoresistant Severe Mental Health Disorders in Children and Adolescents: Functional Abnormalities of Cytochrome P450 2D6"],"prefix":"10.3389","volume":"9","author":[{"given":"Susanne","family":"Th\u00fcmmler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Dor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziella","family":"Leali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Battista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Askenazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Verstuyft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,1,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.clinbiochem.2014.05.065","article-title":"Pharmacogenetics of chronic pain management","volume":"47","author":"Kapur","year":"2014","journal-title":"Clin Biochem"},{"key":"B2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0169-328X(02)00177-8","article-title":"Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain","volume":"103","author":"Chinta","year":"2002","journal-title":"Brain Res Mol Brain Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00702-014-1300-5","article-title":"Clinical applications of CYP genotyping in psychiatry","volume":"122","author":"Spina","year":"2015","journal-title":"J Neural Transm (Vienna)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical Pharmacogenetics Implementation Consortium: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"B5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/00008571-199706000-00004","article-title":"Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution","volume":"7","author":"Marez","year":"1997","journal-title":"Pharmacogenetics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1046\/j.0306-5251.2001.01548.x","article-title":"Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs","volume":"53","author":"Bertilsson","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.phrs.2004.01.004","article-title":"Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population","volume":"50","author":"Scordo","year":"2004","journal-title":"Pharmacol Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1634\/theoncologist.11-2-126","article-title":"Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications","volume":"11","author":"Bernard","year":"2006","journal-title":"Oncologist"},{"key":"B9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1089\/cap.2015.0180","article-title":"Pharmacogenetics of cytochrome p450 enzymes in American Indian and Caucasian Children Admitted to a Psychiatric Hospital","volume":"26","author":"McGrane","year":"2016","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0022-3565(25)20152-5","article-title":"Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles","volume":"278","author":"Aklillu","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1089\/cap.2008.0103","article-title":"Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric psychiatric patients","volume":"19","author":"Prows","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s00431-013-2208-z","article-title":"Neuroleptic malignant syndrome in an adolescent with CYP2D6 deficiency","volume":"173","author":"Butwicka","year":"2014","journal-title":"Eur J Pediatr"},{"key":"B13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/tpj.2014.12","article-title":"Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients","volume":"14","author":"Gass\u00f3","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/dmcn.12470","article-title":"CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study","volume":"10","author":"Youngster","year":"2014","journal-title":"Dev Med Child Neurol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fgene.2014.00073","article-title":"Pharmacogenomics in oncology care","volume":"5","author":"Filipski","year":"2014","journal-title":"Front Genet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/humu.10280","article-title":"CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR","volume":"22","author":"Schaeffeler","year":"2003","journal-title":"Hum Mutat"},{"key":"B17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/00008571-199508000-00005","article-title":"Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology","volume":"5","author":"Steen","year":"1995","journal-title":"Pharmacogenetics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.arcped.2015.02.010","article-title":"Carbamazepine and psychotropic treatment interaction: two case studies of carbamazepine overdosage","volume":"22","author":"Fernandez","year":"2015","journal-title":"Arch Pediatr"},{"key":"B19","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1089\/cap.2015.0103","article-title":"Strong treatment response and high maintenance rates of clozapine in childhood-onset schizophrenia","volume":"26","author":"Kasoff","year":"2016","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S0140-6736(06)69255-6","article-title":"Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother","volume":"368","author":"Koren","year":"2006","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.clpt.2006.01.007","article-title":"Environmental and genetic factors associated with morphine response in the postoperative period","volume":"79","author":"Coulbault","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1177\/070674371405900203","article-title":"Pharmacogenetics of antipsychotics","volume":"59","author":"Brandl","year":"2014","journal-title":"Can J Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.10.008","article-title":"CYP-mediated drug metabolism in the brain impacts drug response","author":"McMillan","year":"2017","journal-title":"Pharmacol Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.2217\/pgs.14.151","article-title":"Polymorphic expression of CYP2C19 and CYP2D6 in the developing and adult human brain causing variability in cognition, risk for depression and suicide: the search for the endogenous substrates","volume":"15","author":"Ingelman-Sundberg","year":"2014","journal-title":"Pharmacogenomics"},{"key":"B26","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/clpt.2009.216","article-title":"High frequency of occurrence of CYP2D6 gene duplication\/multiduplication indicating ultrarapid metabolism among suicide cases","volume":"88","author":"Zackrisson","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/00004714-200004000-00019","article-title":"Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness","volume":"20","author":"Chou","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/1741-7015-11-132","article-title":"Personalized medicine in psychiatry: problems and promises","volume":"11","author":"Ozomaro","year":"2013","journal-title":"BMC Med"},{"key":"B29","first-page":"45","article-title":"Pharmacoresistant severe mental health disorders in children and adolescents: high prevalence of functional abnormalities of cytochrome P450 2D6. Preliminary data and ongoing study protocol","volume":"31","author":"Th\u00fcmmler","year":"2017","journal-title":"Fundam Clin Pharmacol"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fpsyt.2018.00002\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T20:03:39Z","timestamp":1751227419000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fpsyt.2018.00002\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,24]]},"references-count":29,"alternative-id":["10.3389\/fpsyt.2018.00002"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2018.00002","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,24]]},"article-number":"2"}}